The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial


Tranexamic acid, Placebo, Trauma patients, Acute bleeding


Introduction: Because no medication has been approved for coagulation support in trauma, the current study was aimed to evaluate the effectiveness of intravenous injection of Tranexamic acid (TXA) in patients with acute traumatic bleeding.

Methods:  In the current randomized controlled clinical trial, 68 patients with acute bleeding and hemorrhagic shock presentation due to blunt trauma of the abdomen, pelvis, and thorax, randomly assigned into two groups of TXA and placebo.

Results :There was no statistically significant difference between the two groups in terms of Systolic blood pressure, pulse rate, Base excess, serum hemoglobin changes, bleeding volume, the incidence of thrombotic events, and the number of deaths (p>0.05). But Systolic blood pressure, pulse rate, base excess, and serum hemoglobin, changed significantly within each group over time(p<0.05). The median time for the length of hospital stay among the TXA group was lower than the Placebo group (6 days versus 10 days, p: 0.004). Also, there was a significant difference between the two groups about the median of pack cell, Platelet consumption, and bleeding Volume (p<0.05).


 The use of TXA is associated with lower use of blood production and reduced length of hospital stay, however, thrombotic events incidence and mortality rates between the TXA and placebo groups were not different.


[1] Gruen RL, Brohi K, Schreiber M, Balogh ZJ, Pitt V, Narayan M, Maier RV: Haemorrhage control in severely injured patients. The Lancet 2012, 380(9847):1099-1108.
[2] Cannon JW: Hemorrhagic shock. New England Journal of Medicine 2018, 378(4):370-379.
[3] Abbasi H, Bolandparvaz S, Yadollahi M, Anvar M, Farahgol Z: Time distribution of injury-related in-hospital mortality in a trauma referral center in South of Iran (2010–2015). Medicine 2017, 96(21).
[4] Bolandparvaz S, Yadollahi M, Abbasi HR, Anvar M: Injury patterns among various age and gender groups of trauma patients in southern Iran: A cross-sectional study. Medicine 2017, 96(41).
[5] Barbee RW, Reynolds PS, Ward KR: Assessing shock resuscitation strategies by oxygen debt repayment. Shock 2010, 33(2):113-122.
[6] Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ: Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464(7285):104-107.
[7] Tisherman SA, Alam HB, Rhee PM, Scalea TM, Drabek T, Forsythe RM, Kochanek PM: Development of the emergency preservation and resuscitation for cardiac arrest from trauma clinical trial. Journal of Trauma and Acute Care Surgery 2017, 83(5):803-809.
[8] Australian Public Assessment Report for Tranexamic Acid About the Therapeutic Goods Administration (TGA). In., 2010 edn.
[9] US Food and Drug Administration. Highlights of prescribing information. In.
[10] Kolev K, Longstaff C: Bleeding related to disturbed fibrinolysis. British journal of haematology 2016, 175(1):12-23.
[11] Roberts I, Shakur H, Ker K, Coats T: Antifibrinolytic drugs for acute traumatic injury. Cochrane Database of Systematic Reviews 2012(12).
[12] Cole E, Davenport R, Willett K, Brohi K: Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. Annals of surgery 2015, 261(2):390-394.
[13] Levy JH: Antifibrinolytic therapy: new data and new concepts. The Lancet 2010, 376(9734):3-4.
[14] Roberts I, Shakur H, Coats T, Hunt B, Balogun E, Barnetson L, Cook L, Kawahara T, Perel P, Prieto-Merino D: The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technology Assessment (Winchester, England) 2013, 17(10):1.
[15] Collaborators C-: The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. The Lancet 2011, 377(9771):1096-1101. e1092.
[16] Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ: Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Archives of surgery 2012, 147(2):113-119.
[17] Shiraishi A, Kushimoto S, Otomo Y, Matsui H, Hagiwara A, Murata K, Hayakawa M, Maekawa K, Saitoh D, Ogura H: Effectiveness of early administration of tranexamic acid in patients with severe trauma. Journal of British Surgery 2017, 104(6):710-717.
[18] Guyette FX, Brown JB, Zenati MS, Early-Young BJ, Adams PW, Eastridge BJ, Nirula R, Vercruysse GA, O’Keeffe T, Joseph B: Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury: a double-blind, placebo-controlled, randomized clinical trial. JAMA surgery 2021, 156(1):11-20.
[19] Harvin JA, Peirce CA, Mims MM, Hudson JA, Podbielski JM, Wade CE, Holcomb JB, Cotton BA: The impact of tranexamic acid on mortality in injured patients with hyperfibrinolysis. Journal of Trauma and Acute Care Surgery 2015, 78(5):905-911.
[20] Valle EJ, Allen CJ, Van Haren RM, Jouria JM, Li H, Livingstone AS, Namias N, Schulman CI, Proctor KG: Do all trauma patients benefit from tranexamic acid? Journal of Trauma and Acute Care Surgery 2014, 76(6):1373-1378.
[21] Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, Ker K: Anti‐fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane database of systematic reviews 2011(1).
[22] Shakur H, Roberts I, Fawole B, Chaudhri R, El-Sheikh M, Akintan A, Qureshi Z, Kidanto H, Vwalika B, Abdulkadir A: Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. The Lancet 2017, 389(10084):2105-2116.
[23] Moore HB, Moore EE, Gonzalez E, Chapman MP, Chin TL, Silliman CC, Banerjee A, Sauaia A: Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. The journal of trauma and acute care surgery 2014, 77(6):811.
[24] Napolitano LM, Cohen MJ, Cotton BA, Schreiber MA, Moore EE: Tranexamic acid in trauma: how should we use it? Journal of Trauma and Acute Care Surgery 2013, 74(6):1575-1586.
[25] Moore EE, Moore HB, Gonzalez E, Chapman MP, Hansen KC, Sauaia A, Silliman CC, Banerjee A: Postinjury fibrinolysis shutdown: rationale for selective tranexamic acid. The journal of trauma and acute care surgery 2015, 78(6 0 1 0 0 0 0 0 6):S65.
[26] Tencza E, Harrell IV AJ, Sarangarm P: Effect of tranexamic acid administration time on blood product use in urban trauma patients. American Journal of Health-System Pharmacy 2020, 77(Supplement_2):S46-S53.